Group 1 - Company Gilead Sciences-B (01672.HK) announced positive topline pharmacokinetic (PK) data from a randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 in obese subjects (BMI: 30-40 kg/m2) [1] - In the Phase Ib MAD study, the drug exposure levels (AUC0-24h) at steady state were 3,560 ng.h/mL for cohort 1 (20 mg) and 5,060 ng.h/mL for cohort 2 (40 mg) [1] - After 28 days of treatment, the average weight loss was 4.5% for cohort 1 and 6.5% for cohort 2, indicating that higher drug exposure leads to more significant weight loss effects [1] Group 2 - The founder and CEO of Gilead, Dr. Wu Jinzi, stated that higher drug exposure levels for small molecule GLP-1 receptor agonists, including orforglipron, result in more significant weight loss effects [2] - In head-to-head studies in non-human primates, ASC30 showed higher drug exposure than orforglipron, which translated into human clinical studies [2] - Cross-trial comparisons indicated that ASC30's drug exposure in humans is approximately 2.3 to 3.3 times that of orforglipron, suggesting competitive and differentiated potential for ASC30 in treating obesity [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 「基於目前已公開的臨床數據，我們相信對於包括orforglipron在內的小分子GLP-1 受體(GLP-1R)激動劑而言，更高的藥物暴露量會產生更顯著的減重效果，」歌禮 創始人、董事會主席兼首席執行官吳勁梓博士表示，「在非人靈長類動物頭對頭研 究中，ASC30藥物暴露量高於orforglipron，這個數據進一步轉化到了人體臨床研 究中。跨試驗對比顯示，ASC30在人體中的藥物暴露量約為orforglipron的2.3倍至 3.3倍，我們對此感到非常激動。鑒於ASC30更高的藥物暴露量在肥胖受試者中產 生了更顯著的減重效果，我們相信，與orforglipron相比，ASC30每日一次口服片 治療肥胖症具有競爭性及差異化潛力。」 茲提述本公司日期為2025年8月5日的公告，本公司於該公告 ...

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with the Hang Seng Index dropping by 1.27%, losing over 300 points. The Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.4% and 1.47% respectively, with the former barely holding above the 9000-point mark [2] - Major technology stocks, which serve as market indicators, continued to decline in the afternoon. Kuaishou and Meituan fell over 3%, while JD.com dropped by 2.5%. Baidu, NetEase, and Tencent saw declines close to 2%, and Xiaomi fell by 0.56%. Alibaba managed to stay slightly positive [3] Sector Performance - The financial sector, including banks, insurance companies, and Chinese brokerage firms, collectively underperformed, contributing to the overall market decline. The performance of individual stocks continued to be affected by ongoing earnings reports, with property management and real estate stocks experiencing significant drops [3] - Biopharmaceutical stocks faced a collective downturn, particularly in the innovative drug sector, following comments from Trump regarding the rapid imposition of tariffs on pharmaceuticals. This led to notable declines in various biopharma stocks [3] Specific Stock Movements - Several biopharmaceutical companies saw substantial declines, including Kanghao Ya-B (-8.59%), Qiansirui Biotechnology (-7.42%), and Kangfang Biotechnology (-7.10%). Other notable decliners included Xiansheng Pharmaceutical (-6.79%) and Shiyao Group (-6.36%) [3] - In contrast, the rare earth sector remained strong, benefiting from the implementation of supply reforms and multiple catalysts. Apple’s upcoming event on September 9, where the iPhone 17 series is expected to be launched, led to a rise in Apple-related stocks, with Lens Technology (300433) surging nearly 8% and reaching a new high since its listing [4]

Group 1: Market Overview - The Hang Seng Index fell by 0.22%, down 56 points, closing at 25,773 points, while the Hang Seng Tech Index rose by 0.27% [1] - The early trading volume in the Hong Kong stock market reached 133.9 billion HKD [1] Group 2: Company Performances - Pop Mart (09992) surged by 2.88%, with new products selling out instantly and continued high growth in H1 performance [1] - China Duty Free Group (01880) soared over 5% following the opening of its first city duty-free store in Guangzhou, with multiple city stores entering the cultivation phase [1] - Genscript Biotech (01672) increased by 4.7%, as the company raised funds to enhance its weight loss drug development, with Citigroup suggesting attention on the upcoming ASC30 Phase II data [1] - China Gold International (02099) rose by 6.8%, reaching a new high, with core product output exceeding half of the annual guidance and significant expansion potential at the Jiamar mine [1] - Meitu (01357) saw an early gain of over 7%, officially entering the MSCI China Index, with Morgan Stanley optimistic about the company's long-term growth potential [1] - Innovent Biologics (02696) increased by 5.68% post-earnings, with ongoing internationalization strategy and overseas product profits more than doubling in H1 [1] - Angelalign Technology (06699) rose over 7%, with H1 net profit increasing by over 360%, and declared a special interim dividend of 0.46 HKD [1] - Oriental Selection (01797) fell over 7%, with annual net profit declining by 99.67%, while Goldman Sachs maintained a "sell" rating [1][2] Group 3: Financial Results - Kintor Pharmaceutical (01951) dropped by 5.97% post-earnings, reporting a loss of 1.04 billion CNY in H1, compared to a profit in the same period last year [2]

Group 1 - The core point of the article is that Gilead Sciences-B (01672) announced a share placement to raise funds for clinical trials related to obesity treatments, which has positively impacted its stock price [1] - Gilead plans to place 52.4 million shares at HKD 16.45 each, representing a discount of approximately 9.9% from the previous closing price, with net proceeds expected to be HKD 468 million [1] - Approximately 90% of the funds raised will be allocated to the development of subcutaneous and oral peptide candidates for obesity clinical trials [1] Group 2 - The controlling shareholder and founder, Wu Jinzi, will sell 52.4 million shares at HKD 16.45 each and subsequently subscribe to 28.82 million new shares, resulting in a cash-out of HKD 388 million [1] - Citigroup has highlighted the potential of Gilead's small molecule GLP-1 receptor agonist ASC30, with phase II data expected to be released in Q4 this year, which could serve as a key catalyst for the company [1] - Management has indicated that the safety data from the ASC30 phase II A group blind clinical trial has shown good performance with no cases of discontinuation, and a business development partnership for ASC30 is anticipated by mid-2026 [1]

Group 1 - The core point of the article is that Gilead Sciences (歌礼制药) is experiencing a stock price increase following the announcement of a share placement to fund clinical trials for obesity-related peptide drugs [1] - Gilead plans to place 52.4 million shares at HKD 16.45 each, representing a discount of approximately 9.9% from the previous closing price, with net proceeds expected to be HKD 468 million [1] - Approximately 90% of the funds raised will be allocated to the clinical trial development of subcutaneous and oral peptide candidates for obesity [1] Group 2 - The company's controlling shareholder, Wu Jinzi, will sell 52.4 million shares at HKD 16.45 and subsequently subscribe to 28.82 million new shares, resulting in a cash-out of HKD 388 million [1] - Citigroup has released a report highlighting Gilead's potential for its small molecule GLP-1 receptor agonist ASC30, with phase II data expected in Q4 of this year, which could serve as a key catalyst for the company [1] - Management has indicated that the safety data from the ASC30 phase II A group blind clinical trial has shown good performance with no cases of discontinuation, and a business development partnership for ASC30 is anticipated by mid-2026 [1] - Citigroup believes that other candidates like ASC47 and ASC50 have not yet been fully recognized by the market, and new data releases could provide potential upside [1]

Group 1 - Rongchang Biologics (09995.HK) increased by 7.44% [1] - Yongtai Biologics-B (06978.HK) rose by 5.69% [1] - Gilead Sciences-B (01672.HK) saw a gain of 4.41% [1] - Laika Pharmaceuticals-B (02105.HK) experienced a rise of 3.18% [1]

歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认购协议,根据一般 授权配发及发行2882万股新股份。 ...

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认 购协议, 根据一般授权配发及发行2882万股新股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年8月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存 ...